Abbvie Inc

NYSE: ABBV
$175.17
-$3.33 (-1.9%)
Closing Price on January 10, 2025

ABBV Articles

The August 15 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest has significantly decreased.
Credit Suisse has run bullish and bearish scenarios for what the firm feels is a reasonable upside and downside for each of its large cap pharmaceutical stocks.
The July 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest was lower.
In a recent research note, the analysts at Jefferies made a big move by adding Ball Corp. to the firm's well-respected Franchise Picks list of stocks to buy.
A new Jefferies research report features the firm's top pharmaceutical stock picks in order of preference, and AbbVie stays in the top position.
AbbVie released a better-than-expected second-quarter earnings report before the markets opened on Friday.
Despite the fact that energy has tumbled 20% from the highs posted in June, Jefferies remains bullish on the natural gas arena, and with good reason.
Bristol-Myers Squibb released a better-than-expected second-quarter earnings report before the markets opened on Thursday.
The short interest data have been released for the July 15 settlement date. For the selected pharmaceutical stocks, short interest was mixed.
SunTrust Robinson Humphrey feels that the major pharmaceutical companies will outperform the rest of the year, and they cite new products, attractive dividends and solid performance as positives.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. In a study that ranks “perceived strength” of...
24/7 Wall St. has put together a preview of Alphabet, Amazon.com, Facebook and some of the other major companies reporting their quarterly results this week.
With yields plunging and the market getting very pricey, some top pharmaceutical stocks are starting to look like a great total return vehicle for the rest of this year and into 2017.
The June 30 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest decreased.
The broad markets are recovering in the wake of the Brexit and it really appears to be one big head fake. We are also realizing that the Brexit was a great opportunity to buy into the markets and...
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.